
Insights
Forward Through Uncertainty: What Biopharma Leaders Are Saying About the FDA, R&D Investment
Key Takeaways Recent FDA changes have generated uncertainty across the biopharma sector, with questions mounting around approval timelines, shifting trial expectations, and regulatory consistency. In May and June 2025, THL surveyed 100 biopharma decision-makers—spanning early-stage biotechs to top 50 pharma companies—to better understand how today’s regulatory and market dynamics are influencing R&D investment. Most respondents plan to maintain
Healthcare (HC)